# Effect of rEPO in FGF23 in ESRD Patients

> **NCT03803514** · — · COMPLETED · sponsor: **University of Chile** · enrollment: 60 (actual)

## Conditions studied

- Anemia
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Recombinant EPO

## Key facts

- **NCT ID:** NCT03803514
- **Lead sponsor:** University of Chile
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-10-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803514, "Effect of rEPO in FGF23 in ESRD Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03803514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*